Just a moment, the page is loading...
The Supported Studies Programme
For the latest updates on GSK’s response to COVID-19, please click here.

Immunology and Specialty Medicine



Timelines





[The following areas are of interest to the Otilimab ISS/SCS Committee. These were last updated in May 2021.]
Otilimab research proposals are reviewed on a monthly basis. GSK pledges to communicate decisions within 8 weeks. Sponsors will then be invited to submit a full protocol. Please note that approval of a proposal does not guarantee GSK’s support of the protocol.

• GM-CSF expression and myeloid cell activation in COVID-19
• Understanding the underlying immunobiology associated with COVID-19 severity of disease and outcome risk factors
• Understanding the immunobiology of “Long Covid” & association with myeloid cell activation
• Evaluation of clinical outcomes in COVID-19 with therapeutic sequencing or combination therapies
• Timing of treatment in hospitalised COVID-19 patients in need of oxygen support
• Inhibition of disease progression in COVID 19
• Burden of disease costing, HCRU, cost-effectiveness data of COVID-19 therapy
• Unmet needs and risk factors in vaccinated/previously COVID-19 infected patients and the role of immunomodulatory therapies in these populations
Burden of “Long COVID” and long term impact of immunomodulatory therapies


[The following areas are of interest to the Sotrovimab ISS/SCS Committee. These were last updated in May 2021.]
Sotrovimab research proposals are reviewed on a monthly basis. GSK pledges to communicate decisions within 8 weeks. Sponsors will then be invited to submit a full protocol. Please note that approval of a proposal does not guarantee GSK’s support of the protocol.

• Unmet needs and risk factors in vaccinated/previously infected patients and the role of mAbs in these populations
• Burden of Long COVID and long term impact of mAbs
• Effectiveness – VEO & Epi RWE - of the role of mAbs in early treatment
• Virology data on variants, mutations and resistance; and mAbs activity
• Comparative Effectiveness of Vir-7831 vs comparators in early treatment
• Data to describe patient pathways, heath care systems and identify solutions to barriers for mAbs administration
Burden of disease costing, HCRU, cost-effectiveness data

[The following areas are of interest to the Belimumab ISS Committee. These were last updated in May 2021.]

GSK is not accepting new supported study submissions related to Belimumab (Benlysta) at this time. Any accepted submissions, where funding has been confirmed, will be progressed as planned. Please contact your local GSK office if you require further information. We will publish updates at this site should things change. Thank you

Although GSK are more likely to support studies aligned to our current areas of interest for supported studies, we are interested in supporting studies that are innovative and contribute to scientific knowledge relating to a product, a medical condition or advancing a technology.



© 2001-2021 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.